TigogeninCAS# 77-60-1 |
- Sarsasapogenin
Catalog No.:BCN1269
CAS No.:126-19-2
- Sarsaponin
Catalog No.:BCN8293
CAS No.:82597-74-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 77-60-1 | SDF | Download SDF |
| PubChem ID | 99516 | Appearance | White powder |
| Formula | C27H44O3 | M.Wt | 416.64 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Solubility | Soluble in chloroform and DMSO | ||
| SMILES | CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)O)C)C)C)OC1 | ||
| Standard InChIKey | GMBQZIIUCVWOCD-MFRNJXNGSA-N | ||
| Standard InChI | InChI=1S/C27H44O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28H,5-15H2,1-4H3/t16-,17+,18+,19+,20-,21+,22+,23+,24+,25+,26+,27-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Tigogenin is one of steroidal sapogenins which is widely used for synthesizing steroid drugs. It might have protective effect on bone and be helpful in preventing the development of osteoporosis.Tigogenin induces apoptosis, associated with overexpression of COX-2 correlated with overproduction of endogenous PGE2. Tigogenin inhibited of PPARgamma and via p38 MAPK pathway. |
| Targets | COX | PGE | PPAR | p38MAPK |
| In vitro | Inhibition of human rheumatoid arthritis synovial cell survival by hecogenin and tigogenin is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2.[Pubmed: 17786275]Int J Mol Med. 2007 Oct;20(4):451-60.We conducted our study to assess the antiproliferative and proapoptotic potential of hecogenin and Tigogenin, two saponins which are structurally similar to diosgenin.
|
| Cell Research | Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells.[Pubmed: 17363141]Mol Cell Endocrinol. 2007 May 30;270(1-2):17-22.We investigated the effect of Tigogenin on adipocytic and osteoblastic differentiation in mouse bone marrow stromal cells (BMSCs).
|
| Structure Identification | Carbohydr Res. 2014 Jan 13;383:21-6.Efficient one-pot synthesis of tigogenin saponins and their antitumor activities.[Pubmed: 24239606]
|
Tigogenin Dilution Calculator
Tigogenin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | 48.0031 mL | 60.0038 mL |
| 5 mM | 0.48 mL | 2.4002 mL | 4.8003 mL | 9.6006 mL | 12.0008 mL |
| 10 mM | 0.24 mL | 1.2001 mL | 2.4002 mL | 4.8003 mL | 6.0004 mL |
| 50 mM | 0.048 mL | 0.24 mL | 0.48 mL | 0.9601 mL | 1.2001 mL |
| 100 mM | 0.024 mL | 0.12 mL | 0.24 mL | 0.48 mL | 0.6 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tomatidine
Catalog No.:BCN2773
CAS No.:77-59-8
- Cedrol
Catalog No.:BCN8340
CAS No.:77-53-2
- Ursolic acid
Catalog No.:BCN4327
CAS No.:77-52-1
- Chlorthalidone
Catalog No.:BCC4649
CAS No.:77-36-1
- Gibberellins
Catalog No.:BCN2189
CAS No.:77-06-5
- Garcinone C
Catalog No.:BCN4322
CAS No.:76996-27-5
- Euphroside
Catalog No.:BCN6633
CAS No.:76994-07-5
- Notoginsenoside T5
Catalog No.:BCN3727
CAS No.:769932-34-5
- 15-Methoxypinusolidic acid
Catalog No.:BCN4321
CAS No.:769928-72-5
- TPT-260
Catalog No.:BCC5171
CAS No.:769856-81-7
- Cleomiscosin B
Catalog No.:BCN3898
CAS No.:76985-93-8
- Boc-D-2-Nal-OH
Catalog No.:BCC3288
CAS No.:76985-10-9
- Trometamol
Catalog No.:BCC4743
CAS No.:77-86-1
- Citric acid
Catalog No.:BCN5374
CAS No.:77-92-9
- Triethyl citrate
Catalog No.:BCC9186
CAS No.:77-93-0
- D-(-)-Quinic acid
Catalog No.:BCN1029
CAS No.:77-95-2
- (+,-)-Octopamine HCl
Catalog No.:BCC4814
CAS No.:770-05-8
- Dehydropachymic acid
Catalog No.:BCN3648
CAS No.:77012-31-8
- Hypocrellin A
Catalog No.:BCN3396
CAS No.:77029-83-5
- Knightinol
Catalog No.:BCN1913
CAS No.:77053-06-6
- Acetylknightinol
Catalog No.:BCN1914
CAS No.:77053-07-7
- Gadobutrol
Catalog No.:BCC4164
CAS No.:770691-21-9
- 6-O-trans-Feruloylcatalpol
Catalog No.:BCN4323
CAS No.:125205-48-3
- 2H-1-Benzopyran-5-ol
Catalog No.:BCN3581
CAS No.:770729-34-5
Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells.[Pubmed:17363141]
Mol Cell Endocrinol. 2007 May 30;270(1-2):17-22.
We investigated the effect of Tigogenin on adipocytic and osteoblastic differentiation in mouse bone marrow stromal cells (BMSCs). Tigogenin enhanced the proliferation of BMSCs significantly. Tigogenin treatment reduced the adipogenic induction of lipid accumulation, visfatin secretion, and the expressions of peroxisome proliferation-activated receptor (PPAR)gamma2 and adipocyte fatty acid-binding protein (ap)2. Moreover, Tigogenin had no effect on the mitotic clonal expansion. On the other hand, Tigogenin significantly elevated alkaline phosphatase (ALP) activity and the expressions of Cbfa1, collagen type I (COL I) and osteocalcin (OCN), as well as the content of matrix calcium in BMSCs. Further, SB-203580 antagonized the Tigogenin-promoted osteogenesis. These observations suggested that Tigogenin may modulate differentiation of BMSCs to cause a lineage shift away from the adipocytes and toward the osteoblasts, which is at least mediated by inhibition of PPARgamma and via p38 MAPK pathway, and is a potential drug preventing the development of osteoporosis and the related disorders.
Inhibition of human rheumatoid arthritis synovial cell survival by hecogenin and tigogenin is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2.[Pubmed:17786275]
Int J Mol Med. 2007 Oct;20(4):451-60.
We conducted our study to assess the antiproliferative and proapoptotic potential of hecogenin and Tigogenin, two saponins which are structurally similar to diosgenin. We particularly focused our attention on mitogen-activated protein kinase (MAPK) activation in relation to apoptosis but also with the COX-2 expression and activity. Rheumatoid arthritis (RA) synoviocytes were isolated from fresh synovial biopsies obtained from five RA patients undergoing hip arthroplasty. Measurement of cell proliferation was determined using the MTT assay. Apoptosis was evaluated by studying caspase-8, caspase-9 and caspase-3 activities but also by quantification of DNA fragmentation. Quantification of human phospho-MAPKs was realized by ELISA. COX-2 expression was demonstrated by Western blot analysis and COX-2 activity by assay of endogenous prostaglandin E2 (PGE2) production. Tigogenin was more effective than hecogenin in inducing apoptosis in human RA fibroblast-like synoviocytes (FLS) which was caspase dependent but poly(ADP-ribose) polymerase independent and characterized by DNA fragmentation. Our results demonstrated hecogenin- and Tigogenin-induced apoptosis through activation of p38 without affecting the JNK and ERK pathways. Indeed, pretreatment with a p38 inhibitor decreased saponin-induced apoptosis with a significant decrease in DNA fragmentation. Furthermore, the rate of apoptosis induced by hecogenin or Tigogenin was associated with overexpression of COX-2 correlated with overproduction of endogenous PGE2. These new results provide strong evidence that a family of structurally similar plant steroids is capable of inducing apoptosis in human RA FLS with different rates and different signalling pathways. This study also confirms the discussed appearance of the downregulation or upregulation of COX-2 in cell apoptosis as a function of cell type.
Efficient one-pot synthesis of tigogenin saponins and their antitumor activities.[Pubmed:24239606]
Carbohydr Res. 2014 Jan 13;383:21-6.
An efficient synthesis of naturally occurring Tigogenin triglycoside 1a and its three derivatives 1b-d bearing different carbohydrate moieties, as well as their antitumor activities, is described. Partially protected thiogalactosides bearing unprotected 2,4-OH or 4-OH groups were used to facilitate regioselective reactions for one-pot sequential multi-step glycosylation, which has significantly simplified the target molecule synthesis. The synthetic saponins 1a-d exhibited much higher anti-tumor activities than the positive control cisplatin against the human epithelial cervical cancer cell (HeLa) as evaluated by CCK-8 assay.
